Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group
Hitier, Simon; Basaran, Mert; Matus, Geoffrey; Heidenreich, Axel; Bahl, Amit; Malik, Zafar; di Lorenzo, Giuseppe; Bracarda, Sergio; Ardavanis, Alexandros; Parente, Phillip; de Schultz, Wito; Saad, Fred; van Oort, Inge; Gerritsen, Winald R.; Aparicio, Luis M. Anton